Long Non-Coding RNA BCAR4 Binds to miR-644a and Targets TLX1 to Promote the Progression of Bladder Cancer.

Onco Targets Ther

Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, People's Republic of China.

Published: March 2020

Background: Bladder cancer is a serious threat to human health. It is meaningful to study the pathogenesis of bladder cancer. Long non-coding RNAs (lncRNAs) are reported to promote or inhibit bladder cancer development. However, the role of lncRNA BCAR4 in the regulation of bladder cancer remains unclear.

Purpose: This study was to explore the role of lncRNA BCAR4 in the progression of bladder cancer cell.

Methods: RT-PCR was used to examine the expression of BCAR4 and miR-644a. CCK8 assay, colony formation assay, Transwell assay were used to detect the progression of bladder cancer cells after transfecting of indicated plasmids.

Results: The expression of BCAR4 was higher in bladder cancer cell lines than normal urothelial cell line. Moreover, the expression of BCAR4 was associated with the advanced stage and metastasis of bladder cancer. Through knockdown of BCAR4, we discovered that knockdown of BCAR4 significantly decreased the proliferation, migration and invasive abilities of bladder cancer cells. Mechanically, we showed that BCAR4 can bind to miR-644a directly and targets TLX1. Moreover, we also showed that miR-644a was also highly expressed in bladder cancer cells and inhibition of miR-644a or overexpression of TLX1 can increased the migration abilities of bladder cancer caused by knockdown of BCAR4.

Conclusion: We showed that BCAR4 sponged miR-644a to modulate the expression of TLX1 and promote bladder cancer development.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102885PMC
http://dx.doi.org/10.2147/OTT.S232965DOI Listing

Publication Analysis

Top Keywords

bladder cancer
52
bladder
13
cancer
13
progression bladder
12
expression bcar4
12
cancer cells
12
bcar4
10
long non-coding
8
targets tlx1
8
tlx1 promote
8

Similar Publications

: Diabetes mellitus (DM) is associated with worse surgical outcomes, and is a risk factor for bladder cancer and subsequent oncological outcomes. This study evaluated outcomes robot-assisted radical cystectomy (RARC) compared to open radical cystectomy (ORC) in patients with DM. : Data of adults ≥ 18 years old with DM who underwent radical cystectomy were extracted from the United States National Inpatient Sample database 2005-2018.

View Article and Find Full Text PDF

Bladder cancer (BC) is a prevalent urinary malignancy and muscle-invasive bladder cancer (MIBC) is particularly aggressive and associated with poor prognosis. One of MIBC features is the nuclear atypia. However, the molecular mechanism underlying MIBC remains unclear.

View Article and Find Full Text PDF

Exploration of molecular markers is an ongoing focus in the field of bladder cancer research. Based on data from public databases, was identified as upregulated in bladder urothelial carcinoma (BLCA); however, its exact function and regulatory mechanism in this context remain unclear. To investigate the clinical implications of , we examined its levels in 90 BLCA and adjoining normal tissue samples.

View Article and Find Full Text PDF

Feasible approaches for arsenic speciation analysis in foods for dietary exposure assessment: a review.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess

January 2025

Department of Food Science and Nutrition, Hong Kong Polytechnic University, Kowloon, Hong Kong, China.

Arsenic (As) occurs naturally in different forms and oxidation states. Amongst them, inorganic arsenic (iAs) is classified as both genotoxic and carcinogenic whilst other organic arsenic species are considered less toxic. As in rice is mainly present in the form of iAs which therefore poses a health risk to populations that consume rice as a staple food.

View Article and Find Full Text PDF

Introduction: Approximately 75% of bladder cancer cases are non-muscle invasive at diagnosis. Drug development for non-muscle invasive bladder cancer (NMIBC) has historically lagged behind that of other malignancies. No treatment has demonstrated the ability to overcome drug resistance that ultimately leads to recurrence and progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!